A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex)* with megestrol acetate in postmenopausal patients with advanced breast cancer

European Journal of Cancer

Volumn 32, Issue 3, 1996, Pages 404-412

  Jonat, W ^a   Howell, A ^b   Blomqvist, C ^c   Eiermann, W ^d   Winblad, G ^e   Tyrrell, C ^f   Mauriac, L ^g   Roche, H ^h   Lundgren, S ⁱ   Hellmund, R ^j   Azab, M ^j  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d University Women's Hospital   (Germany)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f Plymouth General Hospital   (United Kingdom)

^g INSTITUT BERGONIÉ   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

ⁱ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

Aromatase; Breast neoplasms; Comparative study; Megestrol; Phase III clinical trials; Postmenopause; Random allocation

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; MEGESTROL ACETATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPNEA; EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; MEGESTROL; MIDDLE AGED; NITRILES; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUALITY OF LIFE; REMISSION INDUCTION; SURVIVAL RATE; TRIAZOLES;

EID: 9244245282     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00014-3     Document Type: Article

References (38)

1. Ingle JN, Ahmann DL, Green SJ, et al. Randomised clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with breast cancer. Am J Clin Oncol 1982, 5, 155-160.
2. Lipton A, Harvey HA, Santen RJ, et al. Randomised trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982 42, 3434-3436.
3. Muss HB, Bradley Wells M, Paschold EH, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis - a Phase III trial of the Piedmont Oncology Association. J Clin Oncol 1988, 6 (7), 1098-1106.
4. Patterson AHG, Hanson J, Prichard K, et al. Comparison of antioestrogen and progesterone therapy for initial treatment and consequences of their combination for second line treatment of recurrent breast cancer. Semin Oncol 1990, 17 (Suppl 9), 52-62.
5. Smith IE, Harris AL, Morgan M, et al. Tamoxifen versus aminoglutathimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res 1982 42, 3430(S)-3433(S).
6. Cruz JM, Muss HB, Brockschmidt JK, Evans GW. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy. Semin Oncol 1990, 17 (Suppl 9), 63-67.
7. Willemse PHB, Van der Ploeg E, Sleijfer DTH, Tjabbes T, Van Heelen H. A randomised comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 1990, 26, 337-343.
8. Coombes RC, Powles TJ, Easton D, et al. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. Cancer Res 1987, 47, 2496-2499.
9. Santen RJ, Manni A, Harvey H, Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev 1990, 11(2), 221.
10. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 1989, 16, 83-93.
11. Muss HG. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 1992, 21, 15-26.
12. Bolufer P, Ricart E, Lluch A, et al. Aromatase activity and oestradiol in human breast cancer: its relationship to oestradiol and epidermal growth factor. J Clin Oncol 1992, 10(3), 438-446.
13. Edery M, Goussard J, Dehennin L, Schollen R, Reiffsteck J, Drodowsky MA. Endogenous ooestradiol 17 à concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. Eur J Cancer 1981, 17, 115.
14. Lonning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988, 35, 685-710.
15. Bonneterre J, Coppens H, Mauriac L, et al. Aminoglutethimide in advanced breast cancer: clinical results of a French multicentre randomised trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol 1985, 21, 1153-1158.
16. Cocconi G, Bisagni G, Ceci G, et al. Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomised trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1992, 10, 984-989.
17. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994, 30, 103-111.
18. De Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990, 62, 1034-1038.
19. Hayward JL, Carbone PP, Henson JC, Kumbaoka S, Segalo FFA, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977, 13, 89-94.
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979, 40, 1079-1087.
21. Gale KE, Andersen JW, Tormey DC, et al. Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase II trial comparing aminoglutethimide to tamoxifen. Cancer 1994, 73, 354-361.
22. Coombes RC, Hughes SW, Dowsett M. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. Eur J Cancer 1992, 28A, 1941-1945.
23. Dowsett M, Coombes RC. Second-generation aromatase inhibitor - 4-hydroxyandrostenedione. Breast Cancer Res Treat 1994, 30, 81-87.
24. Perez Carrion R, Alberala Candel V, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994, 5 (Suppl 7), S19-S24.
25. Goss PE, Gwyn KMEH. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994, 12, 2460-2470.
26. Tonkin K, Tritchler D, Tannock I. Criteria of tumour response used in clinical trials of chemotherapy. J Clin Oncol 1985, 3, 870-875.
27. Howell A, Mackintosh J, Jones M, et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988, 24 (1), 1567-1572.
28. Robertson JFR, Williams MR, Todd J, et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989, 23, 469-475.
29. Dixon AR, Jackson L, Chas S, Haybittle J, Blarney RW. A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant breast cancer. Br J Cancer 1992, 66, 402-404.
30. Muss HB, Case LD, Capizzi RL, et al. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a Phase III trial of the Piedmont Oncology Association. J Clin Oncol 1990, 8(11), 1797-1805.
31. Congdon J, Green S, O'Sullivan J, et al. Megestrol acetate (MA) and Aminoglutethimide/Hydrocortisone (Ag/HC) in sequence or combination as second-line endocrine therapy of oestrogen receptor positive metastatic breast cancer. Proc Am Soc Clin Oncol 1991, 10 (Abstract 45), 93.
32. Ingle JN, Green SJ, Ahmann DL, et al. Randomised trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 1986, 4(6), 958-964.
33. Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D. Randomised trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst 1988, 80, 1147-1151.
34. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990, 82, 1127-1132.
35. Von Roenn JH, Armstrong D, Kolter DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Int Med 1994, 121, 393-399.
36. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993, 11, 152-154.
37. Kornblith AB, Hollis DR, Zuckerman E, et al. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. J Clin Oncol 1993, 11, 2081-2089.
38. Lundgren S, Gundersen S, Klepp R, Lonning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 1989, 14, 201-206.